论文部分内容阅读
目的 :评估胰升血糖素C肽释放试验在判断糖尿病 (DM) β细胞功能的临床价值。方法 :33例DM患者静脉注射 1mg胰升血糖素 ,注射前及注射后 6分钟测定血清C -肽值 ,与OGTT试验中C肽变化比较。结果 :1型DM患者两试验C肽最高值与基础值的差 (CPR)显著相关 (r =79) ;2型DM患者血糖未控制前两试验CPR显示无相关性 (r =0 .11) ;而 11例病人血糖控制后重复两试验 ,显示两试验CPR显著相关 (r =0 .6 6 ) ,且OGTT试验中CPR较血糖控制前明显增加 (0 .4 9± 0 .1vs0 .91± 0 .2 9nmol/ ) ,而胰升血糖素试验CPR无明显变化。需胰岛素治疗 2型DM患者 (12例 )胰升血糖素试验的CRP显著低于非胰岛素治疗 (14例 )者 (0 .30± 0 .11vs0 .6 5± 0 .2 1,P <0 .0 1)。结论 :胰升血糖素C肽释放试验较少受慢性高血糖的影响 ,较OGTT更能反应DM患者 β细胞功能。
AIM: To evaluate the clinical value of glucagon C peptide release in determining β-cell function of diabetic (DM). Methods: Thirty - three patients with DM were injected intravenously with 1 mg of glucagon. Serum C - peptide levels were measured before and 6 minutes after injection, which were compared with those of C - peptide in OGTT. Results: There was a significant correlation (r = 0.11) between CPR and CPR in type 2 DM patients (r = 79) ; While 11 patients repeated two tests after the control of blood glucose, showing significant correlation between CPR (r = 0.666) and CPR in OGTT test before blood glucose control was significantly increased (0.49 ± 0. 1 vs 0.91 ± 0 .2 9nmol /), while the glucagon test CPR no significant change. CRP levels in glucagon-like subjects requiring insulin therapy in type 2 DM patients (12 patients) were significantly lower than those in non-insulin-treated patients (0.30 ± 0.11 vs0.65 ± 0.21, P <0). 0 1). CONCLUSIONS: Glucagon C-peptide release assay is less affected by chronic hyperglycemia and more responsive to OGTT than β-cell function in DM patients.